TRON - TRANSLATIONALE ONKOLOGIE ANDER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH

Their core work

TRON is a translational oncology research centre affiliated with Johannes Gutenberg University Mainz, focused on developing personalized cancer immunotherapies. Their core work involves mapping tumor mutations (the "cancer mutanome") and using that information to design individualized mRNA-based cancer vaccines. They also contribute bioinformatics capabilities for neoepitope prediction and have expanded into cardiovascular research through proteomics and extracellular vesicle analysis. TRON sits at the critical junction between fundamental cancer biology and clinical application, translating genomic insights into patient-specific treatments.

What they specialise in

How they've shifted over time

TRON's earliest H2020 involvement (2015) focused on building bioinformatics tools for personalized immunotherapy through APERIM, where they joined as a partner contributing computational expertise. By 2018, they had matured enough to win a prestigious ERC Advanced Grant (SUMMIT) as coordinator, moving from tool-building to leading the full pipeline of mRNA mutanome immunotherapy. Their most recent entry into cardiovascular proteomics (TICARDIO, 2019) suggests they are applying their molecular profiling capabilities beyond oncology.

TRON is moving from computational support roles toward leading mRNA-based therapeutic development, with growing capacity to apply their molecular profiling expertise to diseases beyond cancer.

How they like to work

TRON operates across all consortium roles — coordinator, participant, and third party — which is unusual for only three projects and suggests high flexibility. With 19 unique partners across 7 countries from just 3 projects, they engage in medium-to-large consortia and maintain a broad European network rather than relying on repeat partnerships. Their ERC coordination of SUMMIT (€2.5M) demonstrates they can lead ambitious research programs, while their third-party role in TICARDIO shows willingness to contribute specialized expertise without needing a leading position.

TRON has collaborated with 19 distinct partners across 7 countries through just 3 projects, indicating they work within well-connected European consortia. Their network spans multiple EU member states, consistent with a Germany-based institute with strong ties to the European cancer research and immunology communities.

What sets them apart

TRON is one of the few European centres that combines deep computational genomics (mutanome mapping, neoepitope prediction) with translational mRNA vaccine development — a profile that became globally relevant during the COVID-19 era, given their proximity to BioNTech in Mainz. Their ERC Advanced Grant for mRNA mutanome immunotherapy signals recognition at the highest level of European research excellence. For consortium builders, TRON offers a rare combination: cancer genomics expertise, mRNA therapeutic know-how, and a track record of flexible collaboration across different project roles.

Highlights from their portfolio

• SUMMIT
  ERC Advanced Grant worth €2.5M where TRON served as coordinator — their flagship project on mRNA-based personalized cancer vaccines targeting the tumor mutanome.
• APERIM
  Early project that established TRON's bioinformatics platform for personalized immunotherapy, laying the computational groundwork for their later mRNA vaccine work.
• TICARDIO
  Signals TRON's expansion beyond oncology into cardiovascular research, contributing proteomics and extracellular vesicle expertise as a third party.